BACKGROUND: RE1-silencing transcription factor (REST), a neuronal repressor gene, regulates neuronal stem cell differentiation. Ewing sarcoma may originate from neural crest cells. In the current study, the authors investigated whether REST plays a role in the growth of this tumor. METHODS: REST expression was determined by Western blot analysis and reverse transcription-polymerase chain reaction in 3 human Ewing sarcoma cell lines and 7 patient tumor samples. The role of REST in tumor growth and tumor vascular morphology was determined using a Ewing sarcoma xenograft model. Immunofluorescence staining, Hypoxyprobe, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays were performed to investigate the impact of REST on pericyte marker expression, hypoxia, and apoptosis in vivo. RESULTS: High levels of REST were expressed in all 3 human Ewing sarcoma cell lines and in 6 of the 7 patient tumor samples. Overexpression of EWS-FLI-1 in human mesenchymal stem cells and human neural progenitor cells was found to increase REST expression. Inhibition of EWS-FLI-1 using small interfering RNA decreased REST expression in human Ewing sarcoma cells. Inhibition of REST did not affect EWS-FLI-1, but significantly suppressed tumor growth in vivo, reduced the tumor vessel pericyte markers α- smooth muscle actin (SMA) and desmin, increased hypoxia and apoptosis in tumor tissues, and decreased the expression of delta-like ligand 4 (DLL4) and Hes1. CONCLUSIONS: Inhibition of REST suppressed tumor growth, inhibited pericyte marker expression, and increased tumor hypoxia and apoptosis. Because tumor vessel function has been linked to tumor growth and metastases, REST may be a new therapeutic target in patients with Ewing sarcoma.
BACKGROUND:RE1-silencing transcription factor (REST), a neuronal repressor gene, regulates neuronal stem cell differentiation. Ewing sarcoma may originate from neural crest cells. In the current study, the authors investigated whether REST plays a role in the growth of this tumor. METHODS: REST expression was determined by Western blot analysis and reverse transcription-polymerase chain reaction in 3 humanEwing sarcoma cell lines and 7 patienttumor samples. The role of REST in tumor growth and tumor vascular morphology was determined using a Ewing sarcoma xenograft model. Immunofluorescence staining, Hypoxyprobe, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays were performed to investigate the impact of REST on pericyte marker expression, hypoxia, and apoptosis in vivo. RESULTS: High levels of REST were expressed in all 3 humanEwing sarcoma cell lines and in 6 of the 7 patienttumor samples. Overexpression of EWS-FLI-1 in human mesenchymal stem cells and human neural progenitor cells was found to increase REST expression. Inhibition of EWS-FLI-1 using small interfering RNA decreased REST expression in humanEwing sarcoma cells. Inhibition of REST did not affect EWS-FLI-1, but significantly suppressed tumor growth in vivo, reduced the tumor vessel pericyte markers α- smooth muscle actin (SMA) and desmin, increased hypoxia and apoptosis in tumor tissues, and decreased the expression of delta-like ligand 4 (DLL4) and Hes1. CONCLUSIONS: Inhibition of REST suppressed tumor growth, inhibited pericyte marker expression, and increased tumor hypoxia and apoptosis. Because tumor vessel function has been linked to tumor growth and metastases, REST may be a new therapeutic target in patients with Ewing sarcoma.
Authors: P Lawinger; R Venugopal; Z S Guo; A Immaneni; D Sengupta; W Lu; L Rastelli; A Marin Dias Carneiro; V Levin; G N Fuller; Y Echelard; S Majumder Journal: Nat Med Date: 2000-07 Impact factor: 53.440
Authors: James S Miser; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; Holcolmbe E Grier Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Judy L Felgenhauer; Michael L Nieder; Mark D Krailo; Mark L Bernstein; David W Henry; David Malkin; Sylvain Baruchel; Paul J Chuba; Scott L Sailer; Ken Brown; Sarangarajan Ranganathan; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-10-12 Impact factor: 3.167
Authors: Nikolai D Belyaev; Ian C Wood; Alexander W Bruce; Miyoko Street; Jean-Baptiste Trinh; Noel J Buckley Journal: J Biol Chem Date: 2003-10-15 Impact factor: 5.157
Authors: Maximilian Ackermann; Brent A Morse; Vera Delventhal; Irvith M Carvajal; Moritz A Konerding Journal: Angiogenesis Date: 2012-08-23 Impact factor: 9.596
Authors: Sanjay K Singh; Mohamedi N Kagalwala; Jan Parker-Thornburg; Henry Adams; Sadhan Majumder Journal: Nature Date: 2008-03-23 Impact factor: 49.962
Authors: Jaime Morales-Arias; Paul A Meyers; Marcela F Bolontrade; Nidra Rodriguez; Zhichao Zhou; Krishna Reddy; Alexander J Chou; Nadezhda V Koshkina; Eugenie S Kleinerman Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Yavuz Bayram; Janson J White; Nursel Elcioglu; Megan T Cho; Neda Zadeh; Asuman Gedikbasi; Sukru Palanduz; Sukru Ozturk; Kivanc Cefle; Ozgur Kasapcopur; Zeynep Coban Akdemir; Davut Pehlivan; Amber Begtrup; Claudia M B Carvalho; Ingrid Sophie Paine; Ali Mentes; Kivanc Bektas-Kayhan; Ender Karaca; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski Journal: Am J Hum Genet Date: 2017-07-06 Impact factor: 11.025
Authors: Varalakshmi Katuri; Stephanie Gerber; Xiaofei Qiu; Gregory McCarty; Seth D Goldstein; Hans Hammers; Elizabeth Montgomery; Allen R Chen; David M Loeb Journal: Oncotarget Date: 2014-05-15
Authors: Rubén Fernández-Rodríguez; Francisco Javier Rodríguez-Baena; Estefanía Martino-Echarri; Carlos Peris-Torres; María Del Carmen Plaza-Calonge; Juan Carlos Rodríguez-Manzaneque Journal: Oncotarget Date: 2016-06-07